ABSTRACT: Brain tumor growth results from the relative proportion of cells contained in three populations: a) cycling/proliferative; b) quiescent (G 0 )/static, and c) terminally differentiated/dying. The cycling compartment can be detected by the mouse monoclonal Ki-67 antibody, an available, rapid, safe, sensitive, and specific method for immunostaining of proliferative cells. We report the Ki-67 labeling index (LI) in 48 brain tumors. Malignant brain tumors have elevated Lis, ranging from 6.0% to 56.9%: anaplastic astrocytoma, 8.0 ± 7.3; glioblastoma multiforme, 10.1 ±4.2; germinoma, 11.7; medulloblastoma, 13.1 ±6.6; metastases, 40.3 ± 13.1. By contrast, slow-growing tumors showed lower values (P < .001), approaching 1%: acoustic schwannoma, 0.4 ± 0.6; pituitary adenoma, 1.3 ± 1.9; meningioma, 1.2 ± 1.2; low-grade astrocytoma, < 1; pilocytic astrocytoma, 5.6. Human brain tumors can therefore be ranked according to the percentage of cycling cells with the acoustic schwannoma among the least proliferative and the metastatic carcinoma among the most proliferative. Within a given histotype, the Ki-67 LI may have prognostic and therapeutic implications for the individual patient. Already important for neuro-oncology research, the Ki-67 labeling index should be added to the armamentarium of the clinical neuropathologist to complement the standard histopathologic diagnosis with a cytokinetic analysis of cellular proliferation. RESUME: La proportion de cellules en proliferation dans les tumeurs cerebrales humaines: analyse cytokinetique in situ avec I'anticorps monoclonal Ki-67. La croissance d'une tumeur est le resultat de la proportion relative de trois populations cellulaires: a) en phase proliferative, b) quiescente (G 0 ) et c) completement differenciees. Le compartiment des cellules en proliferation peut etre evalue par immunocytochimie avec I'anticorps monoclonal Ki-67; cette m6thode est facile, rapide et specifique. Nous decrivons l'index de marquage (I.M.) obtenu sur 48 tumeurs c6r6brales provenant de 47 malades operes. Pour les tumeurs malignes 1'I.M. s'est avere" tres eleve, avec des valeurs limites entre 6.0% et 56.9%: 8.0 ± 7.3 pour l'astrocytome anaplasique; 10.1 ± 4.2 pour le glioblastome multiforme; 11.7 pour le germinome; 13.1 ± 6.6 pour le medulloblastome et 40.3 ± 13.1 pour les metastases. Par contre, pour les tumeurs a croissance lente 1'I.M. (P < .001) tourne autour de 1%: 0.4 ± 0.6 pour le schwannome du VIII nerf; 1.3 ± 1.9 pour I'adenome hypophysaire; 1.2 ± 1.2 pour le meningiome; <1 pour l'astrocytome benin; 5.6 pour l'astrocytome pilocytique du cervelet. Les tumeurs cerebrales humaines peuvent etre classees selon le pourcentage de cellules en proliferation: les schwannomes ont les valeurs les plus faibles tandis que les metastases ont les chiffres les plus Sieves. Dans une meme tumeur 1'I.M. evalue par le Ki-67 peut avoir des implications pronostiques et therapeutiques pour un malade en particulier. Cette methode deja importante pour la recherche en neuro-oncologie, devra etre incoporee dans l'arsenal du neuropathologiste afin de completer le diagnostic histopathologique par l'analyse cytokinetique de la prolif6ration cellulaire.
Neoplasms grow because they contain a population of cells cell cycle and are committed to differentiation and cell death; that is expanding as a result of cell division.
1 -2 All tissues conand 3) quiescent cells, G 0 , that are neither cycling nor dying, sist of 3 populations of cells: 3 1) cycling continuously dividing but are dormant and can be induced to reenter the cycle by an cells passing in sequence the various phases of the cell cycleappropriate stimulus. Normal tissues can be classified 2 under M (mitosis), Gj (postmitotic), S-phase (DNA synthesis), and G 2 headings of rapid, slow, or non-proliferating based upon the pro-(premitotic); 2) terminal non-dividing cells that have left the portion of cells that incorporate a pulse of 3 H-thymidine, i.e. the labeling index (L.I.); a) rapid, > 5%; b) slow, ~ 1%; or c) no proliferation, ~ 0%. Most normal tissues are in a steady state where cell growth is balanced by cell death. In neoplasms, an increase in the number of cycling cells in relation to cell loss has important implications in terms of the growth rate of the tumor, the prognosis for the patient, and susceptibility to chemotherapy and radiation therapy. 1 -2 During the past two decades, Hoshino and co-workers have contributed to our understanding of cytokinetics in relation to the biology, 4 therapy, 45 and prognosis 6 -7 of human brain tumors. The normal tissue of the brain, the neurons, 6 glia, 6 and vascular endothelium, 8 are non-proliferative; in no other organ does there exist such a sharp difference in the cytokinetics of normal and neoplastic tissue. 6 Early studies of brain tumor cytokinetics were performed with a pulse of 3 H-thymidine, a marker of the S-phase, given to the patient before surgical removal of the tumor. 2 -5 Modern immunohistochemical techniques using commercially available monoclonal antibodies to BUdR, a thymidine analogue, provide a rapid, reproducible method to perform cell kinetics in situ in human 7 -910 and experimental 8 brain tumors; the tumor labeling index is similar by either BUdR immunohistochemistry comparable to 3 H-thymidine autoradiography. 8 A recent advance in cytokinetic analysis of tumors is the introduction of a monoclonal antibody, Ki-67, that recognizes a nuclear antigen expressed in all phases of the cell cycle, but is absent in quiescent G 0 cells."- 12 Thus Ki-67 provides a straightforward measure of the growth fraction of a tumor, the ratio between the number of cycling cells and the total number of cells. 13 The values of Ki-67 are naturally higher but parallel to those provided by BUdR;
1415 by including G,, G 2 , and M-phase cells, Ki-67 staining allows a complete determination of cell cycle activity and gives more information than that revealed by flow cytometry, 3 H-thymine uptake, or mitosis counting. 16 Unlike isotopic thymidine or BUdR, Ki-67 immunostaining can be performed on frozen sections without pre-operative administration of the agent and therefore is without risk to the patient. 17 Ki-67 immunostaining has proved useful for the evaluation of a variety of human brain tumors 1517 - 25 and tumors outside of the central nervous system (CNS).
13 -14 -16 -26 - 29 The objective of this study is to determine the growth fraction, by Ki-67 immunostaining, in a range of human CNS tumors.
MATERIALS AND METHODS

Tissue Preparation and Staining
Thirty-five consecutive adult human tumors of the CNS, using a well-accepted system of classification, 30 were studied prospectively and 13 pediatric tumors were used from stored frozen tissue. The tissue was sectioned immediately after removal; one portion was fixed in 10% buffered formalin for routine histopathology, the other was quick-frozen in isopentane suspended in liquid nitrogen at -I50°C for 1 minute. The frozen tissue blocks were stored at -80°C. Cryostat sections, 7|im, were air-dried at room temperature for 1 hr., then fixed in methanolacetone (1:1) for 10 min. at -20°C. After rinsing in phosphatebuffered saline (PBS, pH 7.6), endogenous peroxidase was blocked in 0.3% H 2 02 in PBS for 30 min. After a thorough rinse in PBS, the avidin-biotin-peroxidase complex (ABC) method was used (Vectastain ABC Kit, PK4002, Vector Laboratories, Burlingame, CA), consisting of a preincubation with diluted normal horse serum for 20 min., followed by incubation in a humidified chamber with the monoclonal antibody Ki-67 (Dakopatts, USA) at 1:50 dilution for 60 min. at room temperature. After rinsing in PBS, a biotinylated horse secondary antibody against mouse IgG and subsequently to avidin-biotin-peroxidasecomplex for 20 min. each, sections were stained with 3,3'-diaminobenzidine (Sigma Chemicals, St. Louis, MO), 10 mg in 50 ml PBS, and counterstained with Harris hematoxylin. For each section stained with Ki-67, a negative control was performed by omitting the primary antibody, and substituting phosphate buffered saline.
Determination of Ki-67 Labeling Index
The LI was determined using a Bioquant Image Analyzer System (Wild Leitz, Montreal, PQ) composed of a video camera adapted to an Aristoplan microscope (Weild-Leitz, Montreal, PQ) with transmission of the image to a video screen connected to a computer with specialized software. Under a 40X objective, the number of positive and negative cells were scored in 3 or more areas that were maximally positive, a total of 1500 to 2000 cells. A cell was classified positive when part or all of the nucleus was stained. The LI was defined as the proportion of positive cells in relation to the total number of cells evaluated. When the LI was close to zero, reported as < 1% in Tables 1 and 3 , an arbitrary value of 0.02 was assigned to calculate the mean in a particular group.
RESULTS
The Ki-67 monoclonal antibody provided a rapid, distinct, and clear nuclear staining of proliferating tumor cells in a variety of human CNS neoplasms (Figures 1-4) . The Lis of 48 tumors are described together with the histological and clinical information in Tables 1-3 . In general, malignant brain tumorshigh-grade gliomas, glioblastomas, medulloblastomas, and metastatic carcinomas -showed elevated Lis, ranging from 6.0 to 56.9. The Lis (x ± SD) were: anaplastic astrocytomas (n = 3), 8.0 ± 7.3; glioblastomas (n = 11), 10.1 ± 4.2; medulloblastomas (n = 7), 13.1 ± 6.6; and cerebral metastases (n = 6), 40.3 ± 13.1.
These results were in marked contrast with slow-growing tumors P < .001: low-grade astrocytomas (n = 2), x < 1; or extraaxial, nonmalignant tumors: acoustic schwannomas (n = 3), 0.4 ± 0.6; pituitary adenomas (n = 3), 1.3 ± 1.9; and meningiomas (n = 4) 1.2 ± 1.2.
Thus, the human brain tumors could be ranked according to the percentage of cycling cells; the acoustic schwannomas were among the least proliferative and the metastases the most proliferative ( Figure 5 ).
DISCUSSION
The Ki-67 mouse monoclonal antibody represents a rapid, reproducible, readily available, safe, sensitive method to specifically detect the growth fraction of normal, benign, and malignant cell populations. Ki-67 reacts with a nuclear antigen, present in nucleoli, 28 and also show lower Lis than the peripheral areas. 8 Novel therapeutic approaches based upon the manipulation of microenvironmental factors that stimulate or suppress cells proliferation have been proposed for human brain tumors.
1 Ki-67 might prove useful to evaluate novel approaches designed to remove cells from the cycling, replicative pool.
The values of Ki-67 LI in the current study fall within the range of previous series of human brain tumors ( Figure 6 ). Variability in the Lis stems from two inherent limitations, one technical, the other biological. We and others 1624 assume that the proliferative potential is best gauged by the maximal observable change. Therefore, microscopic fields with the highest labeling were selected. An alternative approach is to sample several areas at random, 20 ' 2226 but this method underestimates the growth fraction by combining active and quiescent areas. In gliomas, for example, once transformation begins, the growth rate of the tumor is determined by discrete anaplastic foci that overwhelm non-cycling areas. 4 Furthermore, brain tumors are topographically heterogeneous and factors such as necrosis and proximity to vasculature modify the LI within an individual tumor. 8 There is, however, a clear-cut distinction between the slow growing tumors with growth fractions near 1% and the rapidly proliferating glioblastomas, medulloblastomas, and carcinomas with Lis well above 5%.
The very high growth fraction of metastatic carcinomas (range 26-57%) has been noted previously. 17 - 21 ' 24 In our series, the two patients with Lis greater than 50% had a very short post-operative survival of less than one month. Because the overall growth of the tumor is the net balance between the growth fraction and the cell loss, 34 the rapid growth of metastatic carcinomas is offset, in part, by the cell loss fraction that can be as high as 90%. 35 The recent introduction of a marker for non-proliferating cells 36 may prove useful to complement cytokinetic studies that currently focus only on the cycling pool.
For the gliomas, the slow growing tumors generally show Ki-67 Lis that are below 1%. The unexpectedly high LI (5.6%) for a juvenile pilocytic astrocytoma (case #46) of the cerebellum is consistent with that reported 10 ' 17 and suggests an aggressive variant, 10 since values less than 1% have also been assigned to pilocytic astrocytomas. 22 It is likely, but as yet unproven, that an elevated LI predicts an early recurrence. The tissue from case #14 was diagnosed as a mixed oligoastrocytoma with anaplastic changes in the oligodendrocytic component; case #15 was from the same patient, six months later, with the identical histologic diagnosis at recurrence. The Lis were nearly the same from both surgical specimens. The high LI, in retrospect, may have reflected the potential for early recurrence. Previous studies have reported that oligodendrogliomas and its anaplastic variant 10 21 The medulloblastomas had Ki-67 labeling indices similar to those of adult glioblastomas ( Figure 5 ), and were comparable to the values previously reported. 10 Prolonged storage did not alter the expression of the Ki-67 antigen, as suggested, 22 but instead enabled the reproducible labeling of medulloblastomas and other pediatric tumors.
The germinoma showed an elevated LI (11.7%). The immunostaining was mainly in the small cell population. We were unable to find a previous report of Ki-67 immunostaining of a germinoma for comparison.
Recent studies with flow cytometry support the concept that a higher number of cycling cells predicts a poor prognosis. 37 By contrast, the benign tumors generally show a LI less than 1% (Tables 1-3) . Schwannomas are known to have low growth fractions. I5.iv.i9.2i.22 A few notable exceptions, however, did occur. For example, in one pituitary adenoma (case #24) the LI was 3.5%; a recurrent meningioma (case #22) showed a LI of 2.9%. Infiltration, anaplasia, and recurrences of tumors are linked to There is increasing evidence that the LI carries clinical significance, the higher the LI the more ominous the prognosis. 6 -7 ' 39 The course of a brain tumor is influenced by multiple factors such as size, location, age, degree of edema, necrosis, 7 vascularity, 7 and invasiveness. 40 Nevertheless, the cellular proliferative potential, determined by Ki-67 immunohistochemistry, should be added to the armamentarium of the neuropathologist in the routine assessment of surgical material to provide dynamic cytokinetic data that will complement classical histopathologic diagnosis based upon morphology alone.
